Neil Abramson

Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer

Bernard Fisher, James J. Dignam, Birol Emir et al. · JNCI Journal of the National Cancer Institute · 1997 · 525 citations · Full text

Medicine, Oncology, Breast Oncology +15

Increased Susceptibility to Infection Associated with Abnormalities of Complement-Mediated Functions and of the Third Component of Complement (C3)

Chester A. Alper, Neil Abramson, Richard B. Johnston et al. · New England Journal of Medicine · 1970 · 318 citations

Life Sciences, Immunology, Infectious Diseases +14

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

Bernard Fisher, Stewart Anderson, D. Lawrence Wickerham et al. · Journal of Clinical Oncology · 1997 · 311 citations

Medicine, Oncology, Pharmacotherapy +17

Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23

Bernard Fisher, Stewart Anderson, Elizabeth Tan-Chiu et al. · Journal of Clinical Oncology · 2001 · 275 citations

Medicine, Oncology, Pharmacology +17

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Bernard Fisher, James J. Dignam, Eleftherios P. Mamounas et al. · Journal of Clinical Oncology · 1996 · 235 citations

Medicine, Oncology, Pharmacology +17